Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease
Introduction: We investigated whether monthly assessments of a computerized cognitive composite (C3) could aid in the detection of differences in practice effects (PE) in clinically unimpaired (CU) older adults, and whether diminished PE were associated with Alzheimer's disease (AD) biomarkers...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2021.800126/full |
| _version_ | 1798020107467751424 |
|---|---|
| author | Roos J. Jutten Dorene M. Rentz Dorene M. Rentz Jessie F. Fu Danielle V. Mayblyum Rebecca E. Amariglio Rebecca E. Amariglio Rachel F. Buckley Rachel F. Buckley Michael J. Properzi Paul Maruff Paul Maruff Craig E. Stark Michael A. Yassa Keith A. Johnson Keith A. Johnson Reisa A. Sperling Reisa A. Sperling Kathryn V. Papp Kathryn V. Papp |
| author_facet | Roos J. Jutten Dorene M. Rentz Dorene M. Rentz Jessie F. Fu Danielle V. Mayblyum Rebecca E. Amariglio Rebecca E. Amariglio Rachel F. Buckley Rachel F. Buckley Michael J. Properzi Paul Maruff Paul Maruff Craig E. Stark Michael A. Yassa Keith A. Johnson Keith A. Johnson Reisa A. Sperling Reisa A. Sperling Kathryn V. Papp Kathryn V. Papp |
| author_sort | Roos J. Jutten |
| collection | DOAJ |
| description | Introduction: We investigated whether monthly assessments of a computerized cognitive composite (C3) could aid in the detection of differences in practice effects (PE) in clinically unimpaired (CU) older adults, and whether diminished PE were associated with Alzheimer's disease (AD) biomarkers and annual cognitive decline.Materials and Methods:N = 114 CU participants (age 77.6 ± 5.0, 61% female, MMSE 29 ± 1.2) from the Harvard Aging Brain Study completed the self-administered C3 monthly, at-home, on an iPad for one year. At baseline, participants underwent in-clinic Preclinical Alzheimer's Cognitive Composite-5 (PACC5) testing, and a subsample (n = 72, age = 77.8 ± 4.9, 59% female, MMSE 29 ± 1.3) had 1-year follow-up in-clinic PACC5 testing available. Participants had undergone PIB-PET imaging (0.99 ± 1.6 years before at-home baseline) and Flortaucipir PET imaging (n = 105, 0.62 ± 1.1 years before at-home baseline). Linear mixed models were used to investigate change over months on the C3 adjusting for age, sex, and years of education, and to extract individual covariate-adjusted slopes over the first 3 months. We investigated the association of 3-month C3 slopes with global amyloid burden and tau deposition in eight predefined regions of interest, and conducted Receiver Operating Characteristic analyses to examine how accurately 3-month C3 slopes could identify individuals that showed >0.10 SD annual decline on the PACC-5.Results: Overall, individuals improved on all C3 measures over 12 months (β = 0.23, 95% CI [0.21–0.25], p < 0.001), but improvement over the first 3 months was greatest (β = 0.68, 95% CI [0.59–0.77], p < 0.001), suggesting stronger PE over initial repeated exposures. However, lower PE over 3 months were associated with more global amyloid burden (r = −0.20, 95% CI [−0.38 – −0.01], p = 0.049) and tau deposition in the entorhinal cortex (r = −0.38, 95% CI [−0.54 – −0.19], p < 0.001) and inferior-temporal lobe (r = −0.23, 95% CI [−0.41 – −0.02], p = 0.03). 3-month C3 slopes exhibited good discriminative ability to identify PACC-5 decliners (AUC 0.91, 95% CI [0.84–0.98]), which was better than baseline C3 (p < 0.001) and baseline PACC-5 scores (p = 0.02).Conclusion: While PE are commonly observed among CU adults, diminished PE over monthly cognitive testing are associated with greater AD biomarker burden and cognitive decline. Our findings imply that unsupervised computerized testing using monthly retest paradigms can provide rapid detection of diminished PE indicative of future cognitive decline in preclinical AD. |
| first_indexed | 2024-04-11T16:52:18Z |
| format | Article |
| id | doaj.art-83d53e09c2fc4f4fbc2793c77dfd9731 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-04-11T16:52:18Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-83d53e09c2fc4f4fbc2793c77dfd97312022-12-22T04:13:24ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652022-01-011310.3389/fnagi.2021.800126800126Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's DiseaseRoos J. Jutten0Dorene M. Rentz1Dorene M. Rentz2Jessie F. Fu3Danielle V. Mayblyum4Rebecca E. Amariglio5Rebecca E. Amariglio6Rachel F. Buckley7Rachel F. Buckley8Michael J. Properzi9Paul Maruff10Paul Maruff11Craig E. Stark12Michael A. Yassa13Keith A. Johnson14Keith A. Johnson15Reisa A. Sperling16Reisa A. Sperling17Kathryn V. Papp18Kathryn V. Papp19Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesMelbourne School of Psychological Sciences, University of Melbourne, Melbourne, VIC, AustraliaDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesCogState Ltd., Melbourne, VIC, AustraliaThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, AustraliaDepartment of Neurobiology and Behavior, Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, CA, United StatesDepartment of Neurobiology and Behavior, Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, CA, United StatesDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United StatesIntroduction: We investigated whether monthly assessments of a computerized cognitive composite (C3) could aid in the detection of differences in practice effects (PE) in clinically unimpaired (CU) older adults, and whether diminished PE were associated with Alzheimer's disease (AD) biomarkers and annual cognitive decline.Materials and Methods:N = 114 CU participants (age 77.6 ± 5.0, 61% female, MMSE 29 ± 1.2) from the Harvard Aging Brain Study completed the self-administered C3 monthly, at-home, on an iPad for one year. At baseline, participants underwent in-clinic Preclinical Alzheimer's Cognitive Composite-5 (PACC5) testing, and a subsample (n = 72, age = 77.8 ± 4.9, 59% female, MMSE 29 ± 1.3) had 1-year follow-up in-clinic PACC5 testing available. Participants had undergone PIB-PET imaging (0.99 ± 1.6 years before at-home baseline) and Flortaucipir PET imaging (n = 105, 0.62 ± 1.1 years before at-home baseline). Linear mixed models were used to investigate change over months on the C3 adjusting for age, sex, and years of education, and to extract individual covariate-adjusted slopes over the first 3 months. We investigated the association of 3-month C3 slopes with global amyloid burden and tau deposition in eight predefined regions of interest, and conducted Receiver Operating Characteristic analyses to examine how accurately 3-month C3 slopes could identify individuals that showed >0.10 SD annual decline on the PACC-5.Results: Overall, individuals improved on all C3 measures over 12 months (β = 0.23, 95% CI [0.21–0.25], p < 0.001), but improvement over the first 3 months was greatest (β = 0.68, 95% CI [0.59–0.77], p < 0.001), suggesting stronger PE over initial repeated exposures. However, lower PE over 3 months were associated with more global amyloid burden (r = −0.20, 95% CI [−0.38 – −0.01], p = 0.049) and tau deposition in the entorhinal cortex (r = −0.38, 95% CI [−0.54 – −0.19], p < 0.001) and inferior-temporal lobe (r = −0.23, 95% CI [−0.41 – −0.02], p = 0.03). 3-month C3 slopes exhibited good discriminative ability to identify PACC-5 decliners (AUC 0.91, 95% CI [0.84–0.98]), which was better than baseline C3 (p < 0.001) and baseline PACC-5 scores (p = 0.02).Conclusion: While PE are commonly observed among CU adults, diminished PE over monthly cognitive testing are associated with greater AD biomarker burden and cognitive decline. Our findings imply that unsupervised computerized testing using monthly retest paradigms can provide rapid detection of diminished PE indicative of future cognitive decline in preclinical AD.https://www.frontiersin.org/articles/10.3389/fnagi.2021.800126/fullcomputerized testingremote assessmentpractice effectsdigital biomarkerspreclinical AD |
| spellingShingle | Roos J. Jutten Dorene M. Rentz Dorene M. Rentz Jessie F. Fu Danielle V. Mayblyum Rebecca E. Amariglio Rebecca E. Amariglio Rachel F. Buckley Rachel F. Buckley Michael J. Properzi Paul Maruff Paul Maruff Craig E. Stark Michael A. Yassa Keith A. Johnson Keith A. Johnson Reisa A. Sperling Reisa A. Sperling Kathryn V. Papp Kathryn V. Papp Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease Frontiers in Aging Neuroscience computerized testing remote assessment practice effects digital biomarkers preclinical AD |
| title | Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease |
| title_full | Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease |
| title_fullStr | Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease |
| title_full_unstemmed | Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease |
| title_short | Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease |
| title_sort | monthly at home computerized cognitive testing to detect diminished practice effects in preclinical alzheimer s disease |
| topic | computerized testing remote assessment practice effects digital biomarkers preclinical AD |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2021.800126/full |
| work_keys_str_mv | AT roosjjutten monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT dorenemrentz monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT dorenemrentz monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT jessieffu monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT daniellevmayblyum monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT rebeccaeamariglio monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT rebeccaeamariglio monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT rachelfbuckley monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT rachelfbuckley monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT michaeljproperzi monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT paulmaruff monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT paulmaruff monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT craigestark monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT michaelayassa monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT keithajohnson monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT keithajohnson monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT reisaasperling monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT reisaasperling monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT kathrynvpapp monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease AT kathrynvpapp monthlyathomecomputerizedcognitivetestingtodetectdiminishedpracticeeffectsinpreclinicalalzheimersdisease |